WMSA
NBIX icon

Weiss Multi-Strategy Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-45,000
Closed -$420K – 1068
2013
Q4 		$420K Buy
+45,000
New +$439K 0.01% 668

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Weiss Multi-Strategy Advisers's NBIX Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 11,480 shares — an estimated $1.51M sold.

Weiss Multi-Strategy Advisers first reported a position in NBIX in Q2 2013 and held it in 36 quarters. The position peaked at $10.5M in Q3 2018. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 11,480 Neurocrine Biosciences shares in Q1 2024, an estimated $1.51M.
  • Weiss Multi-Strategy Advisers first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 36 quarters.
  • Weiss Multi-Strategy Advisers's Neurocrine Biosciences position peaked at $10.5M in Q3 2018.
  • 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.